Skip to search formSkip to main contentSkip to account menu

NSC 361456

Known as: NSC-361456 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pyrazine-2-diazohydroxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Phase I and PharmaeoMnetie Study of a New Antineoplastie Agent : Pyrazine Diazohydroxide ( NSC 361456 ) 1
Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent that appears to form DNA adducts via the reactive pyrazine… 
2004
2004
Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo
SummaryPyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial… 
2004
2004
Pyrazine diazohydroxide (NSC-361456)
SummaryPyrazine diazohydroxide (NSC-361456) was identified as an active congener of pyridine 2-diazohydroxide with enhanced… 
2000
2000
Phase II study of pyrazine diazohydroxide (NSC 361456) for advanced non small-cell lung cancer.
Pyrazine diazohydroxide (NSC 361456) (PZDH) was selected for further development after demonstrating more stability than its… 
1998
1998
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Pyrazine diazohydroxide (PZDH) is a novel antitumor agent that forms DNA adducts via the reactive pyrazine diazonium ion. In a… 
1994
1994
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent that appears to form DNA adducts via the reactive pyrazine… 
1994
1994
Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
Pyrazine diazohydroxide (NSC-361456) was identified as an active congener of pyridine 2-diazohydroxide with enhanced stability… 
1993
1993
Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
The sodium salt of pyrazine-2-diazohydroxide (PZDH; NSC 361456) was identified as an active congener of the antitumor lead… 
1987
1987
Synthesis, chemical stability and pre-clinical anti-tumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456).
The synthesis, chemical stability and anti-tumor activity of pyrazine diazohydroxide, sodium salt, a compound that has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)